Chemical compounds studied in this article: TUG-891 (Pubchem CID 57522038) AH7614 (PubChem CID 233085).
Introduction
Macrophages are critical orchestrators of phagocytosis and innate immune function and play central roles in tissue repair via activation, maintenance, and resolution of inflammation within target tissues [1] . This mixed-function modality of macrophages resides in their ability to produce cytokines, growth factors, reactive oxygen species (ROS), reactive nitrogen species (RNS), as well as eicosanoids, including prostaglandins (PG) [1] . The rapid and transient generation of ROS in macrophages is dependent on NADPH oxidase (NOX) holoenzymes, which generate superoxide ions [2] . ROS are intricately involved in regulation of macrophage biology, and along with RNS, facilitate macrophage-mediated antimicrobial responses. Importantly however, ROS also serve purposeful roles in signal transduction and are able to promote inflammatory responses via activation of NF-jB or Jak/STAT signaling in pro-inflammatory M1 polarized macrophages [2] . In a variety of inflammomodulatory cell types, including macrophages, the consequences of this ROS signaling cascade includes upregulation of cyclooxygenase-2 (COX-2) and subsequent synthesis of PG, which in part, direct the inflammatory response [3] [4] [5] [6] [7] . ROS signaling also promotes differentiation of M1 macrophages to the antiinflammatory M2 phenotype, which is responsible for tissue healing and remodeling [8] .
Long chained free-fatty acids (FFA), including the family of n-3 (i.e., omega-3) fatty acids, have long since been known to influence macrophage biology and inflammatory processes (reviewed in [9] [10] [11] ). Over the last decade, a subfamily of G protein-coupled receptors (GPCR) that is activated by endogenous and dietary FFA has been discovered and shown to mediate many of the welldescribed effects of FFA. These free-fatty acid receptors include FFA2 and FFA3, which are agonized by short-chained FFA, as well as FFA1 and FFA4, which are agonized by medium-to-long chained FFA. FFA4, previously termed GPR120, has recently drawn considerable attention due to its profound anti-inflammatory effects (reviewed in 12). Oh and colleagues recently demonstrated that FFA4 agonism can reverse LPS-induced activation of NF-jB and inhibit release of proinflammatory IL-6 and TNF-a from macrophages, in a manner dependent on interaction with b-arrestin-2 partner proteins [13] . In addition, NLRP3 inflammasome assembly/activity, NF-jB translocation, and IL-1b secretion was inhibited via agonism of FFA4 with the n-3 fatty acid docosahexaenoic acid (DHA), in a manner dependent on both Gaq/11 and b-arrestin-2 [14] . Importantly, FFA4 agonism has also been shown to reduce COX-2, but not COX-1, in a b-arrestin-dependent manner [15] , and together, these results suggest a primary role for the FFA4/barrestin axis in modulating the anti-inflammatory effects of FFA in these cells.
In humans, the FFA4 gene yields two protein isoforms, FFA4-L (long; 377 amino acids) and FFA4-S (short; 361 amino acids) ( Fig. 1) , which are identical with the exception of the 16 additional amino acid sequence within the 3 rd intracellular loop [16] , a GPCR domain that typically contributes to partner-protein interactions, downstream signaling, and desensitization. Interestingly, in transfected HEK-293 cells, FFA4-S signals by way of both Gaq/11 and barrestin-2 cascades, whereas FFA4-L fails to couple to Gaq/11 and is intrinsically biased towards only b-arrestin-2 signaling [17] .
Since the GPCR-b-arrestin signaling axis is dependent on receptor phosphorylation by G protein-coupled receptor kinases (GRKs), we have previously studied and reported that upon agonism with DHA, FFA4-S is phosphorylated by GRK6 at Thr 347 , Ser
350
, Ser 357 located within the C-terminal tail [18] . In an elegant series of proteomic studies using the synthetic FFA4 agonist TUG-891, Butcher and colleagues confirmed phosphorylation of these sites, and also revealed agonist-mediated phosphorylation of nearby Thr 349 and Ser 360 [19] . Importantly, this work also demonstrated that three nearby acidic residues, Glu 341 , Asp
348
, and Asp
355
, work in concert with the 5 phosphorylation sites to comprise the negatively charged FFA4 phosphosensor that interacts with b-arrestin [19] . Consistent with this observation, truncation of this C-terminal tail phosphosensor after residue 340 abolished b-arrestin interactability and signaling [19] , demonstrating the importance of the FFA4 C-terminal tail towards its function.
Given the significance of b-arrestin signaling in FFA4 function and the seemingly intrinsic-bias of FFA4-L towards b-arrestin signaling, we wished to examine the role of the C-terminus of both FFA4 isoforms in macrophages. In the present study, we use Raw 264.7 mouse macrophages to show for the first time that FFA4 agonism significantly abrogates NOX-mediated ROS generation. We also assess the ability of FFA4 isoforms and their respective phosphosensor-null C-terminal mutants to modulate ROS generation, COX-2 expression, as well as LPS-mediated NF-jB activity and activation of MAPK. Our results reveal important structurefunction differences between the two FFA4 isoforms, and also show that that the C-terminal tail of FFA4-S is critical to the activity of this isoform.
Materials and methods

Reagents and chemicals
Wild-type (WT) flag-tagged FFA4-S and FFA4-L constructs were generated as previously described [16] . Mutant receptors lacking the b-arrestin phosphosensor [19] were truncated after amino acid MN) and Sigma-Aldrich, respectively, and were later synthesized as described in 2.2. All other chemicals used were obtained at the highest available purity from Thermo Fisher Scientific or Sigma-Aldrich.
Synthesis of TUG-891 and AH7614
The synthesis of TUG-891 or 3-(4-((4-fluoro-4 0 -methyl-[1,1 0 -bi phenyl]-2-yl)methoxy)phenyl)propanoic acid was achieved via a five-step synthetic scheme, as previously described [20] . Briefly, 5-fluoro-2-iodobenzoic acid was reduced to the primary alcohol derivative using lithium aluminum hydride in ether, followed by conversion to the acid chloride 2-(chloromethyl)-4-fluoro-1-iodo benzene using thionyl chloride in dichloromethane. The acid chloride was then coupled with methyl 3-(4-hydroxyphenyl) propanoate using potassium carbonate in acetonitrile. Suzuki cross-coupling was then performed on the resulted methyl 3-(4-((5-fluoro-2-iodobenzyl)oxy)phenyl)propanoate with p-tolylboronic acid in the presence of palladium acetate and triphenyl phosphine in anhydrous dimethylformamide to yield methyl 3-(4-((4-fluoro-
propanoate. The resulted methyl ester was hydrolyzed using lithium hydroxide in tetrahydrofuran to achieve the final compound 3-(4-((4-fluoro-4 0 -methyl- [ H-NMR spectra were consistent with the published data [20] . The synthesis of AH7614 or 4-methyl-N-(9H-xanthen-9-yl)benze nesulfonamide was obtained via a three-step scheme starting with the reductive amination of o-anisidine and salicylaldehyde in the presence of isopropyl alcohol at refluxing temperature to achieve 2-(((2-methoxyphenyl)imino)methyl)phenol, which was followed by its reaction with p-tolualdehyde in the presence of glacial acetic acid and acetic anhydride. The resulted product N-(2-hydroxyben zylidene)-4-methylbenzenesulfonamide was reacted with 2-(trimethylsilyl)phenyl trifluoromethanesulfonate in the presence of potassium fluoride, 18-crown ether and tetrahydrofuran to afford the final product in an overall yield of 58%. The 1 H-NMR spectrum was consistent with the published data [21, 22] .
Cell culture, transfections, and selection
Raw 264.7 macrophages were obtained from ATCC (Manassas, VA) and cultured in 100 mm plates containing Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (Life Technologies, Grand Island, NY). Transfections were performed using LipoD293 reagent (Signagen Laboratories, Gaithersburg, MD) and 8 lg of the respective plasmid DNA, according to the manufacturer's directions. Forty-eight hours after transfection, stable cell selection was initiated and maintained with 1 mg/ml G418-containing selection medium.
RNA extraction, PCR and quantitative real-time PCR
Total cellular RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Gaithersburg, MD), according to the manufacturer's directions. Extracted RNA was reverse-transcribed to cDNA using high capacity cDNA Reverse Transcription (Applied Biosystems, Foster City, CA) and random primers. cDNA templates were amplified for 30 cycles by polymerase chain reaction (PCR) with primers corresponding to FFA4-S-WT, FFA4-L-WT and their corresponding mutants. Quantitative real-time PCR was performed using EvaGreen PCR master mix (Biotium, Fremont, CA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control housekeeping gene with the below primers: FFA4 (N-terminal region): 5 0 -ATGTCCCCTGAATGCGCGCGG-3 0 (FWD) and 5 0 -ATGAG CACCAGCACGGTTGTCTCC-3 0 (REV); Catalase: 5 0 -GCAGATACCTGT GAACTGTC-3 0 (FWD) and 5 0 -GTAGAATGTCCGCACCTGAG-3 0 (REV). GAPDH: 5 0 -ACCACAGTCCATGCCATCAC-3 0 (FWD) and 5 0 -TCCAC CACCCTGTTGCTGTA-3 0 (REV). For data analysis, the DDCt method was used.
ROS generation
The kinetic generation of ROS was induced by stimulation of cells with the superoxide and hydrogen peroxide generator Phorbol 12-myristate 13-acetate (PMA) and monitored by the ROS-sensitive luminol-enhanced chemiluminescent probe L-012 [23] [24] [25] . Briefly, cells were treated with vehicle, TUG-891 (3 lM), or AH 7614 (1 lM) for 1 h, washed with PBS to remove drugs, and detached with a cell scraper. Cells were suspended in HBSS containing 100 lM of L-012 and 100 ll of suspended cells were transferred in triplicate into white 96-well plates, and basal chemiluminescence was recorded immediately in a Tecan Infinite M200.
After 5 min, PMA (1 lM) or vehicle (water) was injected to induce ROS generation and chemiluminescence was recorded for an additional 90 min.
Immunoblotting
Immunoblotting was performed as described previously [16, 18] . Briefly, cells were lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mM NaF, 10 mM Na 2 HPO 4 , pH 7.4) plus protease inhibitor cocktail for 20 min and cleared for insoluble debris by centrifugation at 15,000g for 15 min at 4°C. Protein concentrations were standardized using DC Protein Assay (Bio-Rad, Hercules, CA) and an aliquot of the lysate was denatured in 2X SDS-sample buffer and boiled for 5 min. Equivalent concentrations of lysates were resolved by SDS-PAGE, followed by transfer to PVDF membranes, and immunoblotted with the appropriate antibody. Blots were visualized with HRP-conjugated secondary antibody followed by ECL. Blots were stripped by incubation in glycine IgG stripping buffer for 30-45 min with agitation (25 mM Glycine, 1% SDS, 50°C, pH 2.0) for re-probing. Polyclonal anti-COX-2 antibody (160126) was purchased from Cayman Chemical (Ann Arbor, MI), rabbit anti-FFA4 antibody was purchased from Novus Biologicals (Littleton, CO), rabbit anti-phosphoThr202/Tyr204-p44/p42 MAPK (ERK1/2) and p44/42 MAPK (ERK1/2) antibodies were purchased from Cell Signaling Technologies (Beverly, MA), and anti-actin-HRP antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell viability
Cell viability and inhibition of cell proliferation was measured by reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo lium bromide (MTT) to formazan (Thermo Fisher, Carlsbad, CA). Briefly, cells were seeded in 96-well plates and after overnight incubation, treated with PMA (1 lM) or vehicle (water) for 1 h after which, MTT reagent was added to each well and incubated for 4 h at 37°C. Reduced formazan crystals were dissolved in DMSO and absorbance was measured at 540 nm on a microliter plate reader. For assays that induced cytotoxicity via H 2 O 2, 1 mM H 2 O 2 was added to cells for 1 h, then fresh media was added for an additional 16 h prior to addition of MTT reagent and absorbance reading.
NF-jB reporter assay
NF-jB activity was assessed using the pNFjB-MetLuc2-Reporter assay (Clonetech Laboratories, Mountain View, CA). Briefly, cells were seeded in 100 mm plates and transiently transfected with 5 lg pNFjB-MetLuc2-Reporter or 1 lg pMetLuc2-Control (for normalization of transfection efficiency) vectors, according to manufacturer's protocol. After 24 h, cells were plated in 24 well-plates and treated with TUG-891 (3 lM), 1 h prior to treatment with LPS (100 ng/ml). The cell culture medium was collected after 16 h incubation and analyzed utilizing Ready-To-Glow Secreted Luciferase according to the manufacturer's instructions. NF-jB metridia luciferase activity was normalized to control renilla luciferase values to account for transfection efficiency.
PGE2 production
PGE2 metabolites were assessed by commercially available ELISA (Cayman, Chemical, Mountain View, CA). Briefly, cells were plated in six-well plates and incubated with PMA for 4 h. Fifty microliters of supernatant of culture medium was collected for the determination of PGE2 metabolite concentration according to the manufacturer's directions. Due to differences in absolute concentrations of PGE2 metabolite between experiments, results are expressed as the concentration of PGE2 metabolites normalized to the respective experiment's untransfected control condition.
Data analysis
Autoradiographic data were quantified by densitometric analysis within the linear range using NIH Image J (Bethesda, MD) and graphed using Graphpad Prism 3.0 (San Diego, CA). Data are expressed as mean ± S.E.M for representative experiments repeated at least three independent times. Where not visible, error bars fall within the symbol size. Statistical analysis was performed in Graphpad Instat using a one-way analysis of variance and posthoc Tukey-Kramer's analysis or Student's t-test, as described in the figure legends. Statistical significance is represented as a single symbol for p < 0.05, a double symbol for p < 0.01, and a triple symbol for p < 0.001, as noted in the figure legends.
Results
FFA4 agonism decreases PMA-induced ROS generation in Raw 264.7 macrophages
Since ROS serve primary functions in macrophage biology, we assessed the role of FFA4 in modulating ROS generation in murine Raw 264.7 macrophages. Phorbol-12-myristate 13-acetate (PMA) is known to facilitate the immediate and robust activation of the membrane-bound NADPH oxidase (NOX) machinery to rapidly generate endogenous ROS in superoxide-producing cells, including Raw 264.7 macrophages [26] [27] [28] . True to this nature, PMA (1 lM) stimulated a rapid (within 1 min) and robust increase in ROS generation, which was transiently sustained over a timeframe of 90 min ( Fig. 2A) . The effects of PMA on NOX and subsequent ROS generation are known to be mediated by protein kinase-C (PKC) [7, 26, 27] , and our results confirm that PMA-induced ROS generation was abolished by pretreatment of cells with the PKC inhibitor bisindolylmaleimide II (BIMII) (10 lM, 20 min prior to PMA) (Fig. 2B ). Since Raw 264.7 macrophages have been shown to endogenously express low levels of FFA4 that are agonistresponsive [13] [14] [15] , we next assessed PMA-induced ROS generation in cells treated with synthetic FFA4 modulators. Preincubation of cells for 1 h with the selective FFA4 agonist TUG-891 (3 lM) prior to PMA stimulation resulted in significant abrogation of ROS generatability (Fig. 2C, F) , but had no effect in the absence of PMA, demonstrating that agonism of FFA4 can negativelymodulate ROS generation. On the contrary, pretreatment of cells for 1 h with the selective FFA4 antagonist AH7614 (1 lM) [29] prior to PMA treatment facilitated a statistically significant increase in ROS generation compared to PMA alone (Fig. 2D, F) .
Importantly, pretreatment of cells with TUG-891 (3 lM) in combination with AH7614 (1 lM) prior to PMA treatment lead to complete loss of the agonist's effect, demonstrating that FFA4 is responsible for reversal of PMA-induced ROS generation (Fig. 2E, F) . In order to quantify the entire transient nature of the ROS cycle induced by PMA, and which is modulated by FFA4, we pooled all data and expressed them as the entirety of the area under the curve (AUC) ± SEM of each ROS tracing (Fig. 2F ). To ensure that the effects on ROS seen with TUG-891 were not simply due to the compounds ability to quench or scavenge ROS, we performed cell-free assays with TUG-891, AH7614, or both agents in the presence of exogenous ROS in the form of 100 lM H 2 O 2 . These results show that neither TUG-891 nor AH7614, alone or in combination, affect ROS detection or ROS levels in cell-free systems (Fig. 2G) . Finally, to ensure that the ROS generation seen here was not purely a property of TUG-891, we utilized the endogenous FFA4 agonist DHA as well as the FFA1/FFA4 dual agonist GW9508, which has been used as a selective FFA4 agonist in cells that lack FFA1, as Raw 264.7 macrophages do [13] . DHA (100 lM) decreased PMA-induced ROS generation to a level similar to that seen with TUG-891 (Fig. 2H) , and this effect was again reversed to a level greater than PMA alone upon pretreatment with AH7614 (Fig. 2H) . Interestingly, others have previously shown that GW9508 facilitates an increase in ROS generation from mitochondrial sources and in a manner independent of FFA1/FFA4 [30] . Our data support this observation as GW9508 (1 lM) significantly increased PMA-induced ROS generation (Fig. 2H ) and this effect was dose-dependent (data not shown). This result suggests that GW9508 would not be an acceptable agent for subsequent studies on FFA4-mediated ROS generation.
The C-terminal tail of FFA4-S but not FFA4-L is critical in decreasing PMA-induced ROS generation
Next, we sought to better understand the role of FFA4 isoforms, as well as the importance of FFA4 phosphorylation/b-arrestin interactions in the modulation of ROS in macrophages. Since Raw 264.7 macrophages are difficult to transfect transiently and are known to have poor transfection efficiency, we created Raw 264.7 cell lines that stably expressed wild-type (WT) FFA4-S or FFA4-L, or the C-terminal truncated mutants (Fig. 1) , which lack the b-arrestin phosphosensor and are hence incapable of being phosphorylated or recruiting b-arrestin [18, 19] . Using primers specific to the C-terminal-FLAG epitope used in our constructs [16] (Fig. 3B) . Immunoblotting of whole cell lysates with an anti-FFA4 antibody revealed specific detection of an immunoreactive band at the expected size of 45 kDa in untransfected Raw 264.7 cells (UNTR) that was not present in HEK-293 cells [(À) CON)], which we and others have shown to lack endogenous FFA4 [16, 17] (Fig. 3C) . Importantly, the FFA4 band was increased in the stable transfectants compared to untransfected cells (Fig. 3C) , and was not significantly different amongst transfected cells, confirming similar protein expression of FFA4 constructs in stably transfected cells. Next, we assessed ROS generation in each stable cell line and these results demonstrate that overexpression of FFA4-S-WT nearly abolishes the PMA-induced ROS generation seen in untransfected Raw 264.7 cells (Fig. 3D, F-G) , while the FFA4-S-D340 mutant that lacks amino acids 341-361 comprising the barrestin phosphosensor, only slightly albeit significantly, reduces the PMA effect (Fig. 3D, F) . Similarly, PMA-induced ROS generation was nearly abolished in FFA4-L-WT overexpressing cells, but not to the degree seen with FFA4-S-WT (Fig. 3E-G) . Interestingly, unlike that seen with FFA4-S-D340, overexpression of FFA4-L-D356 was able to decrease PMA-induced ROS generation to the same degree as FFA4-L-WT (Fig. 3E-G) , suggesting that the presence of the additional 16 residues in the longer isoform are able to compensate for the loss of the C-terminal tail. These results confirm that FFA4 can modulate NOX-induced ROS generation and importantly, the Cterminal tail of FFA4-S, but not FFA4-L, is to a large extent required for this effect.
The C-terminal tail of FFA4-S, but not FFA4-L is required for antagonism of PMA-induced ROS generation
Next, we wished to assess the effects of TUG-891 and AH7614 on PMA-induced ROS generation in macrophages stably expressing the given FFA4 constructs. While as seen in Fig. 3, FFA4 -S-WT and FFA4-L-WT expressing cells demonstrated significantly lowered levels of PMA-induced ROS generation compared to untransfected Raw 264.7 cells, to our surprise, agonism with TUG-891 (3 lM, 1 h prior to PMA addition) in these stably overexpressing cells yielded no further reduction of the PMA-induced effect (Fig. 4A and B) , suggesting that receptor overexpression supplies the maximal activity, which is not sensitive to further agonism. On the contrary, receptor blocks the ability of TUG-891 to reduce PMA-induced ROS generation, demonstrating that this effect is modulated directly by FFA4 receptor agonism (n > 5). F, Area under the curves (AUC) for all conditions induced by PMA were quantified (mean ± SEM) using Prism 3.0 and normalized to the maximal response elicited by PMA. G, Cell-free effects of TUG-891 and AH7614 on ROS shows no effects of either agent on ROS detection. H, The FFA4 agonist DHA (100 lM, 1 h prior to PMA treatment) decreases PMA-induced ROS generation (n = 3) and this effect was reversed by AH7614 (1 lM). The FFA4/FFA1 agonist GW9508, which has been shown to increase ROS generation via receptor-independent mechanisms robustly increases PMA-induced ROS generation. Statistical analysis was performed by ANOVA and *** denotes p < 0.001 versus the maximal PMA-response, yyy denotes p < 0.001 versus the TUG-891-treated condition.
blockade by AH7614 (1 lM, 1 h prior to PMA addition) decreased the effect of both FFA4-S-WT and FFA4-L-WT, thereby inhibiting the receptors ability to reduce PMA-induced ROS generation (Fig. 4A, B) . Interestingly, this effect was completely lost in cells overexpressing the FFA4-S-D340 mutant (Fig. 4C ), but not in cells overexpressing FFA4-L-D356 (Fig. 4D) . These results confirm that the C-terminal tail of the shorter isoform is required for the ROSreducing effect, and that the longer isoform overcomes the loss of the C-terminus due to its additional 16 residue segment. To insure that effects on diminished ROS generation in these studies were not simply due to cell toxicity, we assessed cell viability of all stable cell lines. Cell viability did not differ from untransfected Raw 264.7 cells for any of the stable expressants (Fig. 5A) , nor did stable expression of FFA4-S, -L, or mutants inhibit or promote the cytotoxicity induced by exogenously administered ROS in the form of H 2 O 2 (1 mM, 1 h) (Fig. 5A) . PMA has mitogenic properties that could promote cell proliferation or could induce toxicity via generation of ROS. To ensure that PMA treatment in ROS-generation assays did not induce cytotoxicity, or induce proliferation differently in our cell lines, we also performed cell viability assays in control and stable cells exposed to PMA (1 lM) for 4 h. As expected, these data reveal increased cell numbers in PMA treated cells that were not altered by FFA4 expression, and also show no adverse effect on cell viability in any of the stable expressants (Fig. 5B) .
The C-terminal tail of FFA-4-S, but not FFA4-L modulates the receptors ability to reduce COX-2 expression
Since ROS are known to play a part in increasing expression of pro-inflammatory COX-2 in macrophages and other cell types [5] [6] [7] [8] , we next assessed the role of FFA4 in modulating COX-2 expression. In untransfected Raw 264.7 macrophages, PMA treatment (1 lM, 4 h) induced COX-2 expression via PKC, as BIMII (10 lM 1 h prior to PMA) completely abolished the effect (Fig. 6A) . Similarly, treatment of cells with TUG-891 (3 lM, 1 h prior to PMA) in untransfected macrophages significantly reduced PMA-induced COX-2 expression, an effect that was furthered by BIMII (10 lM, 1 h prior to PMA with TUG-891) (Fig. 6A) . Bacterial LPS treatment is also known to induce COX-2 expression in macrophages, an effect that is more robust, though not as rapid as that of PMA. Treatment of cells with LPS (100 ng/ml, 6 h) induced a potent upregulation of COX-2 expression, an effect that was not significantly altered by TUG-891, but was nearly fully blocked by BIMII ( Fig. 6A ; same control as PMA blot). Based on these results, we then assessed PMA-induced COX-2 expression in untransfected Raw 264.7 macrophages and those stably expressing FFA4-S, FFA4-L, or their respective C-terminal truncates. The PMA-induced COX-2 upregulation seen in untransfected cells was significantly decreased in cells expressing FFA4-S-WT and to a lesser degree FFA4-L-WT, but was not significantly decreased in cells expressing either of the respective C-terminal mutants (Fig. 6B) . Here, the effect of FFA4-S-D340 was significantly less than that seen with FFA4-S-WT (Fig. 6B ), but the effect of FFA4-L-WT was only slightly not significantly different than that of FFA4-L-D356. These results also coincided with a significant decrease in PGE2 only in cells expressing FFA4-S-WT (Fig. 6C) , and taken together, demonstrate that FFA4-WT-S has a significant influence on PMA-induced COX-2 expression and subsequent PG synthesis, and the C-terminal phosphosensor plays a major role in this activity. Given the known linkage between ROS generation and COX-2 expression in macrophages, we gauged the role of ROS in the FFA4-mediated effect in the absence or presence of the ROS scavenger N-acetyl-L -cysteine (NAC). In untransfected Raw 264.7 cells, NAC treatment significantly reduced PMA-induced COX-2 expression, confirming the partial-ROS dependence of this effect (Fig. 6D-F) . While cells that stably expressed FFA4-S-WT or FFA4-L-WT had reductions in PMA-induced COX-2 expression (as in Fig. 6B) , there was no additive effect of NAC in these cells (Fig. 6F) , suggesting that the partial ROS-dependency of this effect was already maximally inhibited by receptor expression. Our data reveal a role for FFA4 in reduction of both ROS generation and COX-2 expression, yet, NAC had no additional effect in lowering COX-2 expression in FFA4-WT expressing cells. Hence, we hypothesized that FFA4 expression could modulate cellular adaptations that could explain the effects seen on ROS generation and COX-2 expression. As such, we examined expression of selected oxidant-relevant genes including superoxide dismutase, glutathione reductase, arginase, and catalase to assess potential differences in their expression that may have been induced by overexpression of FFA4 receptors. Using real-time PCR, our results show that Raw 264.7 macrophages which stably overexpressed FFA4-S-WT displayed nearly two-fold higher levels of catalase, the enzyme responsible for reduction of H 2 O 2 , compared to untransfected cells or those expressing FFA4-L-WT or either of the C-terminal truncates (Fig. 6G) . We did not note significant effects on any of the other transcripts within our panel. These results could explain the lack of ability of NAC to further reduce PMA-induced COX-2 expression in FFA4-S-WT expressing cells and may in part, mechanistically explain the role of FFA4-S-WT in reducing COX-2 expression.
FFA4-S but not FFA4-L reduces LPS-mediated NF-jB activity and LPS-mediated ERK1/2 phosphorylation
In Raw 264.7 macrophages, bacterial lipopolysaccharide is known to stimulate NF-jB promotor activity and transcription of inflammatory genes, and this effect is in part associated with mitogen-activated protein kinases, including the extracellularsignal-regulated kinases 1/2 (ERK1/2), phosphorylation and activation of which, plays integral roles in release of proinflammatory cytokines [31] [32] [33] . Hence, we also wished to assess the role of the FFA4-S and FFA4-L b-arrestin phosphosensor on LPSmediated effects to determine if there were similarities to that seen with PMA stimulation. To do so, we assessed NF-jB reporter activity and phosphorylation of ERK1/2. Agonism of endogenous FFA4-S on untransfected Raw 264.7 cells with TUG-891 facilitated reduction in NF-jB promoter activity as assessed by a luciferasepromotor assay (Fig. 7A) , consistent with previous reports [13] . On the contrary to the observed PMA-mediated effects, overexpression of both FFA4-S-WT and FFA4-S-D340, but not FFA4-L-WT or FFA4-L-D356, significantly reduced LPS-mediated NF-jB activity (Fig. 7B) . Notably, while expression of FFA4-S-D340 reduced NF-jB activity, it did so to a significant degree less than that seen in cells expressing FFA4-S-WT (Fig. 7B) , suggesting that this component of receptor activity may be both b-arrestin and Gaq/11-dependent. Similar to results seen in ROS-generation assays, the addition of TUG-891 to cells overexpressing these constructs did not further the effect (data not shown), suggesting that heightened receptor numbers yield maximal activity that is not sensitive to further agonism. In Raw 264.7 macrophages, LPSinduced phosphorylation of ERK1/2, can be activated in part by Ca
2+
-dependent signals through PI3-Kinase, phospholipase-C, or PKC activity [33] [34] [35] , as well as via TAK1 scaffolds that are upheld by b-arrestin-2 [13, 36, 37] . Hence, we next examined the effects of FFA4 isoform and C-terminal mutant expression on LPS-mediated ERK1/2 phosphorylation. Similar to that seen with NF-jB activity, our results show that FFA4-S-WT and FFA4-S-D340, but not FFA4-L-WT or FFA4-L-D356, decrease LPS-mediated ERK1/2 phosphorylation, compared to untransfected Raw 264.7 cells (Fig. 7C-F) . Taken together, these data suggest that there are differences in PMA vs. LPS-mediated pathways affected by FFA4 isoforms, and that while the C-terminal tail of FFA4-S is an important component of its ability to reverse PMA-mediated ROS-generation and COX-2 upregulation, it is not required for LPS-driven NF-jB activity or ERK1/2 phosphorylation. Meanwhile, though FFA4-L-WT decreased PMA-induced ROS generation and COX-2 expression, it had no effect in decreasing LPS-stimulated NF-jB activity . All stable cells also display similar levels of cytotoxicity to UNTR when treated with exogenous H 2 O 2 (1 mM for 1 h, removed, and assayed 16 h later). B, To ensure that PMA treatment does not induce cytotoxicity, experiments were repeated within our PMA-treatment paradigm and no significant differences in cytotoxicity was apparent in any of the stable cells compared to untransfected cells (UNTR).
or phosphorylation of ERK1/2, suggesting that the isoforms have distinct abilities to modulate differential signal transduction cascades.
Discussion
In a previous study, we have shown that agonism of FFA4 with DHA facilitates its rapid phosphorylation at Thr located within the C-terminal tail [18] . Butcher and colleagues subsequent work showed that TUG-891 induces phosphorylation at these sites, and also at nearby Thr 349 and Ser 360 [19] , which together with neighboring acidic residues Glu 341 , Asp
348
, and Asp 355 comprise an area of negative charge that defines the barrestin phosphosensor [19] . Indeed, truncation of the C-terminal tail following Pro 340 formed a mutant FFA4 receptor that failed to interact with, or signal through, b-arrestin-2 but was otherwise signal-capable [19] . In this study, we examined the role that the b-arrestin phosphosensor plays in modulating activities of both FFA4 isoforms in Raw 264.7 macrophages. Our results show that agonism of endogenous FFA4 receptors on the cell-surface of native Raw 264.7 macrophages with TUG-891 significantly reduces PMAinduced ROS generation, an effect that is blocked by the FFA4 antagonist AH7614. Utilizing stable cell lines that express either FFA4 isoform or their respective phosphosensor-null mutant, our results demonstrate that both FFA4-S and FFA4-L can inhibit PMA-induced ROS generation, yet, only removal of the FFA4-S, but not the FFA4-L phosphosensor significantly altered this effect. This result is intriguing and suggests that the presence of the additional 16 amino acid sequence in the 3 rd ICL of FFA4-L offsets the loss of its C-terminal tail in regard to signals that facilitate the blockade of NOX-generated ROS. ROS have been shown to contribute in part to upregulation of COX-2 in a variety of cell types, including macrophages [3] [4] [5] [6] [7] . Meanwhile, agonism of FFA4 with DHA has been shown to decrease COX-2 expression in Raw 264.7 cells via b-arrestin [15] , prompting us to examine the role of loss of the b-arrestin phosphosensor towards this effect. Here, we show that PMA induces upregulation of COX-2 and that expression of FFA4-S significantly abrogates this effect, while expression of FFA4-L was able to do so to a lesser, albeit still significant degree. The decrease in COX-2 expression translated to a significant reduction of PGE2 and its metabolites only in cells expressing FFA4-S, questioning the physiological significance of the FFA4-L induced reduction of COX-2. Notably, our results point to a definitive role for the FFA4-S phosphosensor towards decreasing COX-2 expression, and this result is in line with previous data showing that knockdown of b-arrestin-2 in Raw 264.7 cells abolishes the ability of DHA to reduce COX-2 via FFA4 endogenously expressed on these cells [15] . Our results here also confirm the partial ROS dependence of COX-2 expression, as NAC decreased the PMA-induced effect in untransfected cells, yet this effect was lacking in cells expressing wild-type FFA4 isoforms, which inherently already reduce ROS levels. In these cells, PMAinduced COX-2 expression was not further reduced by NAC treatment, suggesting that the ROS-contribution to this axis was already maximally inhibited upon wild-type FFA4 overexpression. Our results showing upregulation of catalase in only cells which overexpress FFA-S-WT, but not other stable transfectants, confirms this hypothesis and could also mechanistically explain the near full abolishment of PMA-induced ROS generation by the shorter isoform. Expression of FFA4-L-WT also significantly reduced PMAinduced ROS generation, but yet, no significant upregulation in catalase was detected in these cells. Hence, even though the effect of FFA4-S on PMA-induced ROS generation was significantly more profound than that of FFA4-L, catalase upregulation likely only plays a partial role in absolving acute ROS generation. While canonical signaling of GPCRs has been shown to modulate COX-2 expression patterns [38] [39] [40] [41] [42] [43] , a recent study found that the Cterminal tail of the angiotensin-II type 1 GPCR regulated COX-2 expression in a manner independent of canonical signals, including phosphorylation of the C-terminal tail and b-arrestin recruitment [44] . Rather, ATII-1R decreases COX-2 expression via direct enhancement of COX-2 ubiquitination and subsequent proteosomal degradation, an effect that was facilitated by the C-terminal tail in absence of the rest of the GPCR [44] . In this regard, our results did not reveal any significant alterations to COX-2 ubiquitination induced by FFA4 isoforms or C-terminal truncates (data not shown), suggesting that the effects of FFA4 on COX-2 expression are not modulated by simple enhancement of degradation, distinct from that seen with ATII-1R.
FFA4-S agonism and overexpression has a clear role in decreasing ROS generation and COX-2 expression induced by PMA, yet in our studies, agonism of stably expressing cells with TUG-891 did not facilitate a further decrease in either of these effects. On the contrary, antagonism of FFA4 in stably expressing cells served to significantly inhibit the observed decreases in ROS generation. These results were surprising, but suggest that receptor overexpression in our stable cell lines likely encompasses heightened constitutive activity that has reached maximal efficacy and which is not sensitive to further activity upon receptor agonism. Despite a 4-5-fold increase in transcript expression in our stable cell lines, a level that should not signify artefactually massive overexpression, these observations were contradictory to those in untransfected Raw 264.7 cells, where agonism of the low levels of endogenous FFA4 [13] with TUG-891 did elicit both ROS and COX-2 responses. Interestingly, when we examined the effects of TUG-891 on PMAinduced ROS generation in primary intraperitoneal macrophages, which express FFA4 [13] , we failed to detect a robust PMAinduced ROS generation (data not shown), making it difficult to interpret if FFA4 modulates this cascade in these cells. Nonetheless, in our stable Raw 264.7 cell lines, antagonism of stably expressed FFA4 isoforms with AH7614 was able to significantly reduce receptor constitutive activity, confirming the FFA4-mediated mechanism, and corroborating our hypothesis on the lack of further effect upon agonism.
Due to its more ubiquitous expression, much more work has been published on the shorter FFA4 isoform [12] , while very little has been described regarding the function of FFA4-L. A study published in 2012 showed that agonism of FFA4-S transiently expressed in HEK293 cells could signal via both Gaq/11 and barrestin-2 cascades, while importantly, agonism of FFA-L was incapable of promoting Ca
2+
-dependent signals via Gaq/11, yet could signal fully via b-arrestin-2 [17] . Our results shed further light on differences in signal capabilities of the two FFA4 isoforms. While both isoforms were capable of significantly reducing PMAinduced ROS generation and COX-2 expression, only FFA4-S was able to significantly reduce LPS-stimulated NF-jB and ERK1/2 activity. This raises important questions regarding the signaling mechanisms leading to blockade of PKC-dependent functions such as PMA-induced activation of NOX and COX-2 expression, versus LPS/TLR4-dependent cascades. Furthermore, while expression of both FFA4-S-WT and FFA4-S-D340 was able to reduce LPSstimulated NF-jB activity, the C-terminal truncate was significantly less robust at doing so, confirming previous results that showed a b-arrestin component to FFA4 modulation of NF-jB in Raw 264.7 cells [13] . In that study, the FFA4-b-arrestin-2 axis was responsible for sequestration of TAB1 by b-arrestin-2, blocking the TAB1/TAK1 interaction that facilitates NF-jB activity [13] . The ability of FFA4-b-arrestin-2 signaling to inhibit TAK1 effects are also of note given the importance of TAK1 in ROS-dependent upregulation of COX-2 [5] , signifying that the noted effects of FFA4 on ROS generation may also be mediated, at least in part, by b-arrestin-2, a hypothesis that is confirmed by reduced ability of FFA4-S-D340 to decrease ROS generation. However, a curiosity of these data is the lack of effect of FFA4-L-WT, the purported barrestin-biased isoform, on inhibition of NF-jB activity, since neither FFA4-L-WT or FFA4-L-D356 were able to reduce LPSmediated NF-jB or ERK1/2 activities, contrary to their ability to reduce PMA-mediated ROS generation.
In summary, we have found that agonism of FFA4 facilitates decreases in ROS generation and COX-2 expression, and that the C-terminal b-arrestin-phosphosensor of FFA4-S, but not FFA4-L, is in part required for this effect. Meanwhile, our results point to a partial contribution of the C-terminal phosphosensor of FFA4-S in modulating LPS-induced effects, which were completely lacking in the longer isoform.
